Literature DB >> 33580106

Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis.

Andrew F Irvine1,2, Sara Waise3, Edward W Green4, Beth Stuart5, Gareth J Thomas6.   

Abstract

Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with evidence suggesting they represent a heterogeneous population. This study summarises the prognostic role of all proteins characterised in CAFs with immunohistochemistry in non-small cell lung cancer thus far. The functions of these proteins in cellular processes crucial to CAFs are also analysed. Five databases were searched to extract survival outcomes from published studies and statistical techniques, including a novel method, used to capture missing values from the literature. A total of 26 proteins were identified, 21 of which were combined into 7 common cellular processes key to CAFs. Quality assessments for sensitivity analyses were carried out for each study using the REMARK criteria whilst publication bias was assessed using funnel plots. Random effects models consistently identified the expression of podoplanin (Overall Survival (OS)/Disease-specific Survival (DSS), univariate analysis HR 2.25, 95% CIs 1.80-2.82) and α-SMA (OS/DSS, univariate analysis HR 2.11, 95% CIs 1.18-3.77) in CAFs as highly prognostic regardless of outcome measure or analysis method. Moreover, proteins involved in maintaining and generating the CAF phenotype (α-SMA, TGF-β and p-Smad2) proved highly significant after sensitivity analysis (HR 2.74, 95% CIs 1.74-4.33) supporting attempts at targeting this pathway for therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33580106      PMCID: PMC7881148          DOI: 10.1038/s41598-021-81796-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  99 in total

1.  FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation.

Authors:  Jinhua Zhang; Lin Chen; Mingjie Xiao; Chunhui Wang; Zhihai Qin
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

2.  Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer.

Authors:  Roy-Akira Saito; Patrick Micke; Janna Paulsson; Martin Augsten; Cristina Peña; Per Jönsson; Johan Botling; Karolina Edlund; Leif Johansson; Peter Carlsson; Karin Jirström; Kohei Miyazono; Arne Ostman
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

3.  Phenotype molding of stromal cells in the lung tumor microenvironment.

Authors:  Diether Lambrechts; Els Wauters; Bram Boeckx; Sara Aibar; David Nittner; Oliver Burton; Ayse Bassez; Herbert Decaluwé; Andreas Pircher; Kathleen Van den Eynde; Birgit Weynand; Erik Verbeken; Paul De Leyn; Adrian Liston; Johan Vansteenkiste; Peter Carmeliet; Stein Aerts; Bernard Thienpont
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

4.  The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.

Authors:  Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2014-03       Impact factor: 11.151

Review 5.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

6.  Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma.

Authors:  Shinya Neri; Genichiro Ishii; Hiroko Hashimoto; Takeshi Kuwata; Kanji Nagai; Hiroshi Date; Atsushi Ochiai
Journal:  Int J Cancer       Date:  2015-02-20       Impact factor: 7.396

7.  Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

Authors:  Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Journal:  Cancer Biol Ther       Date:  2007-08-14       Impact factor: 4.742

8.  Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro.

Authors:  Lingzhi Hong; Huiming Sun; Xiaojing Lv; Di Yang; Jinan Zhang; Yi Shi
Journal:  Mol Biol Rep       Date:  2009-08-18       Impact factor: 2.316

9.  FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.

Authors:  Hyung-Ok Lee; Stefanie R Mullins; Janusz Franco-Barraza; Matthildi Valianou; Edna Cukierman; Jonathan D Cheng
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  8 in total

Review 1.  The Outside-In Journey of Tissue Transglutaminase in Cancer.

Authors:  Livia Elena Sima; Daniela Matei; Salvatore Condello
Journal:  Cells       Date:  2022-05-29       Impact factor: 7.666

2.  Increase in Chymase-Positive Mast Cells in Recurrent Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland.

Authors:  Ichita Kinoshita; Denan Jin; Masaaki Higashino; Tetsuya Terada; Yoshitaka Kurisu; Shinji Takai; Ryo Kawata
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

Review 3.  Technique integration of single-cell RNA sequencing with spatially resolved transcriptomics in the tumor microenvironment.

Authors:  Hailan Yan; Jinghua Shi; Yi Dai; Xiaoyan Li; Yushi Wu; Jing Zhang; Zhiyue Gu; Chenyu Zhang; Jinhua Leng
Journal:  Cancer Cell Int       Date:  2022-04-19       Impact factor: 6.429

4.  Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers.

Authors:  Yuan Cai; Qingchun He; Wei Liu; Qiuju Liang; Bi Peng; Jianbo Li; Wenqin Zhang; Fanhua Kang; Qianhui Hong; Yuanliang Yan; Jinwu Peng; Zhijie Xu; Ning Bai
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

5.  Correlation of tumor microenvironment-related markers with clinical outcomes in patients with squamous cell carcinoma of the lung.

Authors:  Mayu Sugai; Naoki Yanagawa; Shunsuke Shikanai; Mai Hashimoto; Hirotaka Saikawa; Mitsumasa Osakabe; Hajime Saito; Makoto Maemondo; Tamotsu Sugai
Journal:  Transl Lung Cancer Res       Date:  2022-06

Review 6.  Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Jason Hongting Leung; Benjamin Ng; Wei-Wen Lim
Journal:  Cells       Date:  2022-07-21       Impact factor: 7.666

Review 7.  Cancer-Associated Fibroblasts Influence the Biological Properties of Malignant Tumours via Paracrine Secretion and Exosome Production.

Authors:  Martin Vokurka; Lukáš Lacina; Jan Brábek; Michal Kolář; Yi Zhen Ng; Karel Smetana
Journal:  Int J Mol Sci       Date:  2022-01-16       Impact factor: 5.923

Review 8.  CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion.

Authors:  Gurcan Gunaydin
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.